Usefulness of Combined Metabolic–Volumetric Indices of 18F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer

Abstract

Purpose The purpose of this study was to investigate the usefulness of metabolic-volumetric indices of 18 Ffluorodeoxy-D-glucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for the evaluation of neoadjuvant chemotherapy outcomes in breast cancer. Methods Twenty-four patients with locally advanced breast cancer were enrolled in the study. They underwent baseline 18 F-FDG PET/CT scan and received four or six cycles of neoadjuvant chemotherapy, interim 18 F-FDG PET/CT was done after second cycle of chemotherapy. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary lesions were calculated. Reduction rates of these parameters were obtained between baseline and interim 18 F-FDG PET/ CT. Chemotherapy outcomes were assessed using tumor size reduction rate and histological grading system (Miller and Payne system). Reduction rates of SUVmax, MTV, and TLG correlated with chemotherapy outcomes. Results MTV and TLG reduction rates showed significant correlation with tumor size reduction rate (R00.68, P0 0.0004; R00.62, P00.002, respectively). However, SUVmax reduction rate showed no significant correlation. MTV and TLG reduction rates were significantly higher in responders than nonresponders, as determined by Miller and Payne system (P<0.0007, P<0.002). However, SUVmax reduction rate showed no significant difference. On ROC analysis, the area under the MTV and TLG curves was 0.886, and that of SUVmax was 0.743. Sensitivity, specificity, positive predictive value, and negative predictive value to predict histopathologic response were the same for MTV and TLG, and the values were 100 %, 85.7 %, 83.3 %, and 100 %, respectively (at the reduction rate of 93.2 % for MTV, and 95.8 % for TLG). Conclusion Changes of metabolic-volumetric indices successfully reflected the neoadjuvant chemotherapy outcomes. MTV and TLG could be robust indices in discriminating pathologic responder as SUVmax, after neoadjuvant chemotherapy.

Novel Use of Rituximab in a Case of Riedel's Thyroiditis Refractory to Glucocorticoids and Tamoxifen

“…Although there was no reduction in the size of her thyroidal and mediastinal masses, there were significant decreases in SUVmax in both sites and the area of FDGpositivity in her mediastinal mass, indicative of reduced inflammatory activity in keeping with a treatment response. It is of interest that reduction of SUVmax is at least as clinically important as tumor size as an index of oncological response (31,32).…”

Volume-based Metabolic Tumor Response to Neoadjuvant Chemotherapy Is Associated with an Increased Risk of Recurrence in Breast Cancer

“…However, most of the PET studies in patients who have undergone NAC have common limitations of small patient numbers, variable cutoff value of percentage change in the standardized uptake value (SUV), and limited use of metabolic response parameters with only SUV. Recent studies showed that the relative decrease in volume-based PET parameters after two cycles of NAC could be used to predict pathologic complete response more accurately than SUV (6)(7)(8). Many investigators studied only the association between PET parameters and pathologic complete response and did not evaluate the relationship between PET parameters and prognosis in patients who failed to achieve pathologic complete response.…”

Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result

“…18 F-FDG PET data allow a quantitative evaluation of glucose metabolism of tumor. Although a lot of previous studies have reported the clinical usefulness using SUV max and volumetric parameters, these conventional parameter-based analyses have several limitations [4,5,[11][12][13]. These parameters are classified into histogram-based parameters, so they also have the short-comings of histogram analysis.…”